<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04321473</url>
  </required_header>
  <id_info>
    <org_study_id>WE_REMAIN_EBC_19</org_study_id>
    <nct_id>NCT04321473</nct_id>
  </id_info>
  <brief_title>Registry on Left Main Coronary Artery Bifurcation Percutaneous Intervention</brief_title>
  <acronym>WE REMAIN EBC</acronym>
  <official_title>Web-based Registry on Left Main From the Euro Bifurcation Club (WE REMAIN EBC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>G. d'Annunzio University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Azienda Sanitaria Locale n. 2 - Lanciano Vasto Chieti</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Clínico Universitario de Valladolid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VZW Cardiovascular Research Center Aalst</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinica Mediterranea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw, Poland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>San Raffaele University Hospital, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto Dante Pazzanese de Cardiologia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Centre Maribor</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinica Di Montevergine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Hospital Centre Zagreb</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Centre of Serbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chiba University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Université Paris-Sud</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Reina Sofia de Cordoba</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mount Sinai Hospital, New York</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Pablo Tobón Uribe</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pauls Stradins Clinical University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Monastir, Tunis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>G. d'Annunzio University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The slowly accruing evidence on the treatment of patients with left main coronary artery
      (LMCA) disease drove evolution in guidelines, that currently establish equivalent safety and
      efficacy for percutaneous coronary intervention (PCI) as compared to surgery, with a class of
      recommendation that is subjected to the extension and complexity of concomitant coronary
      artery disease, as assessed by the SYNTAX score.

      The severity of LMCA disease, although extremely relevant due to the extent of the supplied
      myocardium, is often difficult to assess with traditional angiography, due to lack of
      appropriate angiographic views, absence of a true &quot;reference&quot; segment, interaction with the
      intubating catheter. Intravascular techniques with either imaging or functional assessment
      have been variously tested, although with a disturbing rate of discordant results; moreover,
      they are frequently underused for a number of reasons, including the additional time needed
      to assess both left anterior descending (LAD) and left circumflex (LCx) arteries, technical
      challenges, costs and the small risk associated with maneuvering such devices. Fractional
      flow reserve (FFR) measured from the coronary angiogram (FFRangio) alone recently documented
      a high diagnostic accuracy compared with pressure-wire derived FFR.

      As for the anatomical localization, the majority of LMCA lesions occur at the bifurcation,
      where PCI results are less favourable. The distal LMCA differs from the other bifurcations in
      several characteristics: a) a notable mismatch between the LMCA and the left anterior
      descending (LAD) artery, hampering the selection of an adequately sized stent, b) the
      presence of a trifurcation, with a large ramus arising from LMCA in about 10% of cases, c)
      the presence of left or co-dominant circulation, with the LMCA supplying all or nearly all
      left ventricular myocardium in about 15% of cases.

      Therefore, although the European Bifurcation Club (EBC) recommends a provisional side branch
      approach in most cases of distal LMCA disease, the threshold for placing a second stent in
      the side branch may be lower in lesions located on LM bifurcation compared with non-LMCA
      bifurcations. As for double stenting, the evidence is controversial and a consensus is
      lacking. Moreover, the optimal treatment of patients with LM trifurcations is still
      undefined.

      The aim of this study is therefore to determine the optimal strategy for the treatment of LM
      bifurcated lesions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PCI access site and technique will be left at the operator's discretion, as well as
      antithrombotic management.

      No limitation will be applied for the technique of PCI. As regards data collection and
      endpoints, Case Report Form (CRF) will be entered on a web-based platform, where study
      participants will be able to access and retrieve data at any time during study progress.

      In-hospital outcomes will be recorded; all patients discharged alive will be followed up with
      a 30-day, 6-month, and 1-year telephone interview.

      On a center-to-center voluntary basis, pre-PCI and post-PCI angiographic images (made blind
      regarding patients' identity) will be sent to a study angiographic core-lab for Quantitative
      Angiography Substudy. The images will be processed using a validated quantitative coronary
      angiography (QCA) Bifurcation software to assess quantitative data describing bifurcation
      geometry before and after LMCA PCI. In the Quantitative Angiography Substudy, on exploratory
      bases, FFRangio data reconstructed by angiographic software will be tested against stenosis
      LMCA lesion severity and LMCA PCI result.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Major adverse cardiac events (MACE)</measure>
    <time_frame>12 months</time_frame>
    <description>The composite of: death from any cause, myocardial infarction (MI), stent thrombosis (ST), defined as definite, probable or possible following the Academic Research Consortium.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>12 months</time_frame>
    <description>All-cause death and cardiovascular death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MI</measure>
    <time_frame>12 months</time_frame>
    <description>Myocardial Infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ST</measure>
    <time_frame>12 months</time_frame>
    <description>Stent thrombosis (definite, probable or possible)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital MACE</measure>
    <time_frame>12 Months</time_frame>
    <description>Composite of death, MI and ST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (TVR)</measure>
    <time_frame>12 Months</time_frame>
    <description>Target Vessel Revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>12 Months</time_frame>
    <description>The occurrence of major bleeding, as a bleeding defined by the academic research consortium (BARC)- classified as type 3 (a, b or c) or 5 bleeding event</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Coronary Arteriosclerosis</condition>
  <condition>Left Main Coronary Artery Disease</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PCI on left main</intervention_name>
    <description>PCI on left main coronary stenosis</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a diagnosis of documented silent ischemia, stable angina, or ACS, undergoing
        PCI with single or multiple DES for the treatment of lesion located at LM coronary
        bifurcation and defined as a diameter stenosis of ≥50% by visual estimation.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ≥18 years of age with a diagnosis of documented silent ischemia, stable
             angina, or acute coronary syndrome (ACS).

          -  PCI with single or multiple drug-eluting stent (DES) for the treatment of lesion
             located at LMCA bifurcation and defined as a diameter stenosis of ≥50% by visual
             estimation.

        Exclusion Criteria:

          -  Patients who cannot give informed consent or have a life expectancy of ≤12 months;

          -  Pregnant or nursing mothers. Women of child-bearing age will be asked if they are
             pregnant or think that they may be pregnant.

          -  Contraindication or suspected intolerance to anticoagulant (heparin, bivalirudin) or
             oral antiplatelet therapy (aspirin, clopidogrel, prasugrel, ticagrelor).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Zimarino, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Sanitaria Locale n. 2 - Lanciano Vasto Chieti</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marco Zimarino, MD, PhD</last_name>
    <phone>+39 3476045261</phone>
    <email>m.zimarino@unich.it</email>
  </overall_contact>
  <link>
    <url>https://p2bito.org/</url>
    <description>Web CRF Platform</description>
  </link>
  <reference>
    <citation>Zimarino M, Briguori C, Amat-Santos IJ, Radico F, Barbato E, Chieffo A, Cirillo P, Costa RA, Erglis A, Gamra H, Gil RJ, Kanic V, Kedev SA, Maddestra N, Nakamura S, Pellicano M, Petrov I, Strozzi M, Tesorio T, Vukcevic V, De Caterina R, Stankovic G; EuroBifurcation Club. Mid-term outcomes after percutaneous interventions in coronary bifurcations. Int J Cardiol. 2019 May 15;283:78-83. doi: 10.1016/j.ijcard.2018.11.139. Epub 2018 Dec 2.</citation>
    <PMID>30528620</PMID>
  </reference>
  <reference>
    <citation>Lassen JF, Holm NR, Banning A, Burzotta F, Lefèvre T, Chieffo A, Hildick-Smith D, Louvard Y, Stankovic G. Percutaneous coronary intervention for coronary bifurcation disease: 11th consensus document from the European Bifurcation Club. EuroIntervention. 2016 May 17;12(1):38-46. doi: 10.4244/EIJV12I1A7. Review.</citation>
    <PMID>27173860</PMID>
  </reference>
  <reference>
    <citation>Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Jüni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO; ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019 Jan 7;40(2):87-165. doi: 10.1093/eurheartj/ehy394. Erratum in: Eur Heart J. 2019 Oct 1;40(37):3096.</citation>
    <PMID>30165437</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 23, 2020</study_first_submitted>
  <study_first_submitted_qc>March 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2020</study_first_posted>
  <last_update_submitted>March 25, 2020</last_update_submitted>
  <last_update_submitted_qc>March 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>G. d'Annunzio University</investigator_affiliation>
    <investigator_full_name>Marco Zimarino</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Case Report Forms (CRF) will be shared among partecipating centers</ipd_description>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>12 Months</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

